Trial Profile
A Randomized Phase 3 Study of Two Doses of Alimta [Pemetrexed] in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed a Prior Platinum-Containing Chemotherapy
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 06 Sep 2021
Price :
$35
*
At a glance
- Drugs Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- 04 Sep 2021 This trial has been completed in Spain (End Date: 15 Apr 2008), according to European Clinical Trials Database record.
- 01 May 2008 Results published in the Annals of Oncology.
- 06 Sep 2005 New trial record.